Ildong’s ‘Besivo’ shows equivalence and improved safety to Viread
“Besivo, a chronic hepatitis B treatment, is a product which proved equivalent efficacy and improved safety to Viread.”
Ildong Pharmaceutical held a press conference for ‘Besivo Tab,’ a new chronic hepatitis B treatment which recently acquired commercialization approval, with the subject ‘New Ch...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
